Genedrive (GB:GDR) has released an update.
Genedrive PLC, a leader in point-of-care pharmacogenetic testing, has announced a significant leadership change with the departure of CEO James Cheek and the appointment of former CSO Dr. Gino Miele PhD as his successor. Dr. Miele, who has been with the company since 2011, has played a crucial role in product development and regulatory approvals, contributing to the company’s strong position in the market. The company remains focused on expanding its product portfolio and market presence to drive growth.
For further insights into GB:GDR stock, check out TipRanks’ Stock Analysis page.
